Implantable Device to Detect Rejection of Cardiac Allograft

Tech ID: cze000217


The most effective treatment for patients with end-stage heart failure or who suffer from severe coronary artery disease is heart transplantation. The leading cause of death after heart transplantation is allograft rejection, either chronic or acute, where the recipient's immune system attacks the transplanted organ. To combat allograft rejection, recipients of a heart transplant must take a regimen of immunosuppressant drugs for the remainder of their life. To mitigate the effects of immunosuppressant therapy, the dosage the transplant recipient receives is limited as much as possible. The balance between limiting the dosage of the immunosuppressant regimen and combating transplant rejection is maintained by constant monitoring of the transplant recipient to guide immunosuppressant therapy. Currently, the standard method for monitoring rejection of a cardiac allograft is through endomyocardial biopsy. Despite its widespread use, endomyocardial biopsy has several serious limitations. Consequently, there exists a need in the art for alternative methods for detection of cardiac allograft rejection.


Technology Description
To answer this unmet need, Dr. Lawrence Czer from the Cedars-Sinai Medical Center developed an implantable device which comprises a plurality of sensors to measure physiological parameters, such as core body temperature, cardiac output, and electrical activity (e.g., voltages) generated by the cardiac allograft, at specified intervals after the transplant procedure. These measured parameters are subsequently compared with baseline data to detect rejection of the cardiac allograft.


Stage of Development
Concept only


The current invention seeks to monitor the efficacy of immunosuppressant therapy and evaluate the degree of rejection of a cardiac allograft. Several systems, however, have attempted to use measurements of the electrical signals from a transplanted heart to predict cardiac rejection in transplant recipients. The current invention provides advantages for detecting cardiac allograft rejection over prior art devices and methods. One advantage of the current inventive device is that the device does not require the implantation of pacemaker leads into the tissue of the cardiac allograft. As a result, the current inventive device has a reduced risk of infection after implantation. Moreover, the current inventive device correlates the electrical signal data from the cardiac allograft with other physiological data such as overall cardiac output, and core body temperature, to provide a more robust assessment of cardiac allograft rejection.


Evaluation of the degree of rejection of a cardiac allograft.


Intellectual Property
•       US patent 8523780 granted.

Patent Information:
For Information, Contact:
Julien Brohan
Lawrence Czer